BIOCONTROL TECHNOLOGY INC
8-K, 1999-03-01
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: AFL CIO HOUSING INVESTMENT TRUST, NSAR-B, 1999-03-01
Next: DMI FURNITURE INC, SC 13G, 1999-03-01




                                                                 
               SECURITIES AND EXCHANGE COMMISSION
                                
                     Washington, D.C.  20549
                                
                            FORM 8-K
                                
                         CURRENT REPORT
                                
             Pursuant to Section 13 or 15(d) of the
                 Securities Exchange Act of 1934
                                
                       ___________________
                                
                                
  Date of Report (Date of earliest event reported) February 24,
                              1999

                   BIOCONTROL TECHNOLOGY, INC.
     (Exact name of registrant as specified in its charter)
                                                                 

     Pennsylvania                                   0-10822
                           25-1229323
        (State of other jurisdiction         (Commission File
Number)               (IRS Employer
                        of incorporation)
                       Identification No.)


      300 Indian Springs Road, Indiana, Pennsylvania 15701
    (Address of principal executive offices)           (Zip Code)

                                
Registrant's telephone number, including area code (412) 349-1811
                                
                                

_________________________________________________________________
                 (Former name or former address,
                  if changes since last report.)
                                
                                
                                
                                



Item 1.   Change in Control of Registrant.
          Not applicable.

Item 2.   Acquisition or Disposition of Assets.
          Not applicable.

Item 3.   Bankruptcy or Receivership.
          Not applicable.

Item 4.   Changes in Registrant's Certifying Accountant
          Not applicable.

Item 5.   Other Events.

          Bioconrol Technology, Inc. has submitted a PMA Shell to
          US FDA for its Diasensor 1000 Noninvasive Blood Glucose
          Monitor.  This outline of modules is necessary to
          complete a Premarket Approval Application, the first
          step in submission of Modular PMA.

Item 6.   Resignation of Registrant's Directors.
          Not Applicable

Item 7.   Financial Statement, Pro Forma Financial Information
          and Exhibits.

          (a)  Financial Statements and Businesses Acquired - Not
               Applicable.

          (b)  Pro Forma Financial Information - Not Applicable.

          (c)  Exhibits - Press Release.

                           SIGNATURES

      Pursuant to the requirement of the Securities Exchange  Act
of  1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.

                                   BIOCONTROL TECHNOLOGY, INC.

                                   by  /s/   Fred E. Cooper
                                         Fred E. Cooper, CEO

DATED:  February 24, 1999



                                     BICO
                                       BIOCONTROL TECHNOLOGY, INC
                            2275 Swallow Hill Road, Building 2500
                                            Pittsburgh, PA  15220
Press Release

Investors                                       Media
Diane McQuaide                                  Susan Taylor
1.412.429.0673  phone                           1.412.429.0673 phone
1.412.279.9690  fax                             1.412.279.5041 fax



               BIOCONTROL SUBMITS PMA SHELL TO FDA

     Pittsburgh,  PA - February 24, 1999 - Biocontrol Technology,
Inc.  (OTCBB:BICO) announced today that it has  submitted  a  PMA
Shell  to  the  US  Food and Drug Administration  (FDA)  for  its
Diasensor 1000 Noninvasive Blood Glucose Monitor.  The PMA  Shell
is an outline of those sections or modules that will be necessary
to  complete a Premarket Approval Application (PMA)  and  is  the
first  step in the company's planned submission of a Modular  PMA
for  approval to market the Diasensor 1000 in the United  States.
Once  the  PMA  shell is approved by the FDA,  the  company  will
submit  the  first module of the Application for  the  Diasensor,
which is already approved for the European market.
     Biocontrol   Technology  has  its   corporate   offices   in
Pittsburgh, PA and is involved in the development and manufacture
of  biomedical  devices and environmental  products.   Subsidiary
Diasensor.com, Inc., also located in Pittsburgh, PA, markets  the
Diasensor.    Diasensor.com  owns  the  patent,   marketing   and
distribution  rights  to  the sensor  while  Biocontrol  has  the
exclusive   rights   to   the  research   and   development   and
manufacturing of the sensor.
     
WEBSITE:  www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER:  1.800.357.6204








© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission